DPP‐4 Inhibitor Linagliptin Attenuates Aβ‐induced Cytotoxicity through Activation of AMPK in Neuronal Cells
CNS Neuroscience & Therapeutics2015Vol. 21(7), pp. 549–557
Citations Over TimeTop 10% of 2015 papers
Edy Kornelius, Chih‐Li Lin, Hsiu‐Han Chang, Hsin‐Hua Li, Wen‐Nung Huang, Yi‐Sun Yang, Yingli Lu, Chiung‐Huei Peng, Chien‐Ning Huang
Abstract
Taken together, our findings suggest linagliptin can restore the impaired insulin signaling caused by Aβ in neuronal cells, suggesting DPP-4 inhibitors may have therapeutic potential for reducing Aβ-induced impairment of insulin signaling and neurotoxicity in AD pathogenesis.
Related Papers
- → Evidence for antifibrotic incretin-independent effects of the DPP-4 inhibitor linagliptin(2015)22 cited
- → Pharmacokinetic and pharmacodynamic evaluation of linagliptin for the treatment of type 2 diabetes mellitus, with consideration of Asian patient populations(2016)26 cited
- → Linagliptin: A Novel Methylxanthin Based Approved Dipeptidyl Peptidase-4 Inhibitor(2012)14 cited
- → Preferential prescribing and utilization trends of diabetes medications among patients with renal impairment: Emerging role of linagliptin and other dipeptidyl peptidase 4 inhibitors(2017)11 cited
- → DPP-4 抑制劑 Linagliptin對抗β類澱粉蛋白導致神經毒性之保護作用(2014)